Indication

SHH-activated and TP53 Wildtype

1 clinical trial

1 product

4 drugs

Clinical trial

Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma

Status: Completed, Estimated PCD: 2022-09-30

Drug

Drug

Product

Drug

Drug